PIMJS
CCCC icon

PKO Investment Management Joint-Stock’s C4 Therapeutics CCCC Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35,000
Closed -$264K – 136
2022
Q2 		$264K Buy
+35,000
New +$308K 0.04% 120

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

PKO Investment Management Joint-Stock's CCCC Position: Q3 2022 in Review

PKO Investment Management Joint-Stock sold out of C4 Therapeutics (CCCC) in Q3 2022, closing a stake of 35,000 shares — an estimated $264K sold.

PKO Investment Management Joint-Stock first reported a position in CCCC in Q2 2022 and held it in 1 quarter. The position peaked at $264K in Q2 2022. 114 funds tracked by Wall St. Rank hold CCCC as of Q3 2022.

  • PKO Investment Management Joint-Stock reported no remaining C4 Therapeutics position as of Q3 2022 after selling out during the quarter.
  • PKO Investment Management Joint-Stock sold 35,000 C4 Therapeutics shares in Q3 2022, an estimated $264K.
  • PKO Investment Management Joint-Stock first reported a position in C4 Therapeutics in Q2 2022 and held it in 1 quarter.
  • PKO Investment Management Joint-Stock's C4 Therapeutics position peaked at $264K in Q2 2022.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2022.

Based on PKO Investment Management Joint-Stock's 13F filing for Q3 2022, filed 13 Mar 2025.